107 related articles for article (PubMed ID: 37262000)
1. Evaluation of the Cherokee Nation Hepatitis C Virus Elimination Program - Cherokee Nation, Oklahoma, 2015-2020.
Essex W; Feder M; Mera J
MMWR Morb Mortal Wkly Rep; 2023 Jun; 72(22):597-600. PubMed ID: 37262000
[TBL] [Abstract][Full Text] [Related]
2. Identification and Clinical Management of Persons with Chronic Hepatitis C Virus Infection - Cherokee Nation, 2012-2015.
Mera J; Vellozzi C; Hariri S; Carabin H; Drevets DA; Miller A; Reilley B; Essex W; Gahn D; Lyons L; Leston J; Ward JW
MMWR Morb Mortal Wkly Rep; 2016 May; 65(18):461-6. PubMed ID: 27172175
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Cherokee Nation Hepatitis C Virus Elimination Program in the First 22 Months of Implementation.
Mera J; Williams MB; Essex W; McGrew KM; Boeckman L; Gahn D; Miller A; Durham D; Fox J; David C; Ritter T; Jones S; Bouse S; Galvani A; Ward JW; Drevets DA; Carabin H
JAMA Netw Open; 2020 Dec; 3(12):e2030427. PubMed ID: 33337496
[TBL] [Abstract][Full Text] [Related]
4. Assessing the Feasibility, Acceptability, and Effectiveness of a Pilot Hepatitis C Screening Program at Food Distribution Sites in Cherokee Nation, Oklahoma.
Essex W; Mera J; Comiford A; Winters A; Feder MA
J Community Health; 2023 Dec; 48(6):982-993. PubMed ID: 37531046
[TBL] [Abstract][Full Text] [Related]
5. A Regional Analysis of Hepatitis C Virus Collaborative Care With Pharmacists in Indian Health Service Facilities.
Geiger R; Steinert J; McElwee G; Carver J; Montanez R; Niewoehner J; Clark C; Reilley B
J Prim Care Community Health; 2018; 9():2150132718807520. PubMed ID: 30348039
[TBL] [Abstract][Full Text] [Related]
6. NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
[TBL] [Abstract][Full Text] [Related]
7. Three Years of Progress Toward Achieving Hepatitis C Elimination in the Country of Georgia, April 2015-March 2018.
Tsertsvadze T; Gamkrelidze A; Chkhartishvili N; Abutidze A; Sharvadze L; Kerashvili V; Butsashvili M; Metreveli D; Gvinjilia L; Shadaker S; Nasrullah M; Adamia E; Zeuzem S; Afdhal N; Arora S; Thornton K; Skaggs B; Kuchuloria T; Lagvilava M; Sergeenko D; Averhoff F
Clin Infect Dis; 2020 Aug; 71(5):1263-1268. PubMed ID: 31563938
[TBL] [Abstract][Full Text] [Related]
8. The Role of Screening and Treatment in National Progress Toward Hepatitis C Elimination - Georgia, 2015-2016.
Nasrullah M; Sergeenko D; Gvinjilia L; Gamkrelidze A; Tsertsvadze T; Butsashvili M; Metreveli D; Sharvadze L; Alkhazashvili M; Shadaker S; Ward JW; Morgan J; Averhoff F
MMWR Morb Mortal Wkly Rep; 2017 Jul; 66(29):773-776. PubMed ID: 28749925
[TBL] [Abstract][Full Text] [Related]
9. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia.
Averhoff F; Shadaker S; Gamkrelidze A; Kuchuloria T; Gvinjilia L; Getia V; Sergeenko D; Butsashvili M; Tsertsvadze T; Sharvadze L; Zarkua J; Skaggs B; Nasrullah M
J Hepatol; 2020 Apr; 72(4):680-687. PubMed ID: 31811882
[TBL] [Abstract][Full Text] [Related]
10. National Progress Toward Hepatitis C Elimination - Georgia, 2015-2016.
Gvinjilia L; Nasrullah M; Sergeenko D; Tsertsvadze T; Kamkamidze G; Butsashvili M; Gamkrelidze A; Imnadze P; Kvaratskhelia V; Chkhartishvili N; Sharvadze L; Drobeniuc J; Hagan L; Ward JW; Morgan J; Averhoff F
MMWR Morb Mortal Wkly Rep; 2016 Oct; 65(41):1132-1135. PubMed ID: 27764081
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
Jacobson IM; Lawitz E; Kwo PY; Hézode C; Peng CY; Howe AYM; Hwang P; Wahl J; Robertson M; Barr E; Haber BA
Gastroenterology; 2017 May; 152(6):1372-1382.e2. PubMed ID: 28193518
[TBL] [Abstract][Full Text] [Related]
12. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.
Seeff LB; Hoofnagle JH
Clin Liver Dis; 2003 Feb; 7(1):261-87. PubMed ID: 12691470
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System.
Ioannou GN; Beste LA; Chang MF; Green PK; Lowy E; Tsui JI; Su F; Berry K
Gastroenterology; 2016 Sep; 151(3):457-471.e5. PubMed ID: 27267053
[TBL] [Abstract][Full Text] [Related]
14. The impact of COVID-19 pandemic on the 2020 hepatitis C cascade of care in the Republic of Georgia.
Gamkrelidze A; Handanagic S; Shadaker S; Turdziladze A; Tsereteli M; Getia V; Aslanikashvili A; Surguladze S; Gvinjilia L; Kuchuloria T; Tskhomelidze I; Armstrong PA
Public Health; 2022 Apr; 205():182-186. PubMed ID: 35305459
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment.
Liu CH; Peng CY; Kao WY; Yang SS; Shih YL; Lin CL; Tsai MK; Lee CY; Chang CC; Wu JH; Liu CJ; Su TH; Tseng TC; Chen PJ; Kao JH
Aliment Pharmacol Ther; 2022 Feb; 55(4):434-445. PubMed ID: 34773272
[TBL] [Abstract][Full Text] [Related]
16. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis virus (HCV) diagnosis and access to treatment in a UK cohort.
Adland E; Jesuthasan G; Downs L; Wharton V; Wilde G; McNaughton AL; Collier J; Barnes E; Klenerman P; Andersson M; Jeffery K; Matthews PC
BMC Infect Dis; 2018 Sep; 18(1):461. PubMed ID: 30217169
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C treatment outcomes among patients treated in co-located primary care and addiction treatment settings.
Ngo BV; James JR; Blalock KL; Jackson SL; Chew LD; Tsui JI
J Subst Abuse Treat; 2021 Dec; 131():108438. PubMed ID: 34098298
[TBL] [Abstract][Full Text] [Related]
19. The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: Impact of direct acting antivirals.
Bartlett SR; Yu A; Chapinal N; Rossi C; Butt Z; Wong S; Darvishian M; Gilbert M; Wong J; Binka M; Alvarez M; Tyndall M; Krajden M; Janjua NZ
Liver Int; 2019 Dec; 39(12):2261-2272. PubMed ID: 31444846
[TBL] [Abstract][Full Text] [Related]
20. Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system.
Zhang M; O'Keefe D; Craig J; Samley K; Bunreth V; Jolivet P; Balkan S; Marquardt T; Dousset JP; Le Paih M
Lancet Gastroenterol Hepatol; 2021 May; 6(5):371-380. PubMed ID: 33743883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
